
Yevgeny Valenrod
Examiner (ID: 18322)
| Most Active Art Unit | 1621 |
| Art Unit(s) | 1628, 1621, 1672 |
| Total Applications | 1499 |
| Issued Applications | 1070 |
| Pending Applications | 102 |
| Abandoned Applications | 358 |
Applications
| Application number | Title of the application | Filing Date | Status |
|---|---|---|---|
Array
(
[id] => 20178217
[patent_doc_number] => 20250262175
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2025-08-21
[patent_title] => COMPOUNDS AND COMBINATIONS THEREOF FOR TREATING NEUROLOGICAL AND PSYCHIATRIC CONDITIONS
[patent_app_type] => utility
[patent_app_number] => 19/204307
[patent_app_country] => US
[patent_app_date] => 2025-05-09
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 59383
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 103
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 19204307
[rel_patent_id] =>[rel_patent_doc_number] =>) 19/204307 | Compounds and combinations thereof for treating neurological and psychiatric conditions | May 8, 2025 | Issued |
Array
(
[id] => 20163918
[patent_doc_number] => 20250255964
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2025-08-14
[patent_title] => RAS INHIBITORS
[patent_app_type] => utility
[patent_app_number] => 19/196471
[patent_app_country] => US
[patent_app_date] => 2025-05-01
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 71058
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 36
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 19196471
[rel_patent_id] =>[rel_patent_doc_number] =>) 19/196471 | RAS INHIBITORS | Apr 30, 2025 | Pending |
Array
(
[id] => 20098881
[patent_doc_number] => 20250228817
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2025-07-17
[patent_title] => ENHANCING AUTOPHAGY OR INCREASING LONGEVITY BY ADMINISTRATION OF UROLITHINS
[patent_app_type] => utility
[patent_app_number] => 19/170782
[patent_app_country] => US
[patent_app_date] => 2025-04-04
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 75096
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -12
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 19170782
[rel_patent_id] =>[rel_patent_doc_number] =>) 19/170782 | ENHANCING AUTOPHAGY OR INCREASING LONGEVITY BY ADMINISTRATION OF UROLITHINS | Apr 3, 2025 | Pending |
Array
(
[id] => 20098881
[patent_doc_number] => 20250228817
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2025-07-17
[patent_title] => ENHANCING AUTOPHAGY OR INCREASING LONGEVITY BY ADMINISTRATION OF UROLITHINS
[patent_app_type] => utility
[patent_app_number] => 19/170782
[patent_app_country] => US
[patent_app_date] => 2025-04-04
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 75096
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -12
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 19170782
[rel_patent_id] =>[rel_patent_doc_number] =>) 19/170782 | ENHANCING AUTOPHAGY OR INCREASING LONGEVITY BY ADMINISTRATION OF UROLITHINS | Apr 3, 2025 | Pending |
Array
(
[id] => 20098880
[patent_doc_number] => 20250228816
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2025-07-17
[patent_title] => ENHANCING AUTOPHAGY OR INCREASING LONGEVITY BY ADMINISTRATION OF UROLITHINS
[patent_app_type] => utility
[patent_app_number] => 19/170770
[patent_app_country] => US
[patent_app_date] => 2025-04-04
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 75193
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -8
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 19170770
[rel_patent_id] =>[rel_patent_doc_number] =>) 19/170770 | ENHANCING AUTOPHAGY OR INCREASING LONGEVITY BY ADMINISTRATION OF UROLITHINS | Apr 3, 2025 | Pending |
Array
(
[id] => 20212591
[patent_doc_number] => 12409225
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2025-09-09
[patent_title] => Ras inhibitors
[patent_app_type] => utility
[patent_app_number] => 19/070930
[patent_app_country] => US
[patent_app_date] => 2025-03-05
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 39
[patent_figures_cnt] => 42
[patent_no_of_words] => 71719
[patent_no_of_claims] => 23
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 57
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 19070930
[rel_patent_id] =>[rel_patent_doc_number] =>) 19/070930 | Ras inhibitors | Mar 4, 2025 | Issued |
Array
(
[id] => 20134985
[patent_doc_number] => 20250242029
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2025-07-31
[patent_title] => RAS INHIBITORS
[patent_app_type] => utility
[patent_app_number] => 19/068133
[patent_app_country] => US
[patent_app_date] => 2025-03-03
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 71377
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -1
[patent_words_short_claim] => 26
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 19068133
[rel_patent_id] =>[rel_patent_doc_number] =>) 19/068133 | Ras inhibitors | Mar 2, 2025 | Issued |
Array
(
[id] => 20048368
[patent_doc_number] => 20250186590
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2025-06-12
[patent_title] => RAS INHIBITORS
[patent_app_type] => utility
[patent_app_number] => 19/062331
[patent_app_country] => US
[patent_app_date] => 2025-02-25
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 70879
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -2
[patent_words_short_claim] => 5
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 19062331
[rel_patent_id] =>[rel_patent_doc_number] =>) 19/062331 | Ras inhibitors | Feb 24, 2025 | Issued |
Array
(
[id] => 20049827
[patent_doc_number] => 20250188049
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2025-06-12
[patent_title] => ADVANTAGEOUS BENZOFURAN COMPOSITIONS FOR MENTAL DISORDERS OR ENHANCEMENT
[patent_app_type] => utility
[patent_app_number] => 19/053277
[patent_app_country] => US
[patent_app_date] => 2025-02-13
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 89665
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -28
[patent_words_short_claim] => 69
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 19053277
[rel_patent_id] =>[rel_patent_doc_number] =>) 19/053277 | Advantageous benzofuran compositions for mental disorders or enhancement | Feb 12, 2025 | Issued |
Array
(
[id] => 20200346
[patent_doc_number] => 12403111
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2025-09-02
[patent_title] => Compositions and methods for treating neurodevelopmental disorders
[patent_app_type] => utility
[patent_app_number] => 19/042105
[patent_app_country] => US
[patent_app_date] => 2025-01-31
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 29
[patent_figures_cnt] => 44
[patent_no_of_words] => 21368
[patent_no_of_claims] => 20
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 22
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 19042105
[rel_patent_id] =>[rel_patent_doc_number] =>) 19/042105 | Compositions and methods for treating neurodevelopmental disorders | Jan 30, 2025 | Issued |
Array
(
[id] => 19752719
[patent_doc_number] => 20250041284
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2025-02-06
[patent_title] => TREATMENT OF NEUROLOGICAL DISORDERS
[patent_app_type] => utility
[patent_app_number] => 18/927451
[patent_app_country] => US
[patent_app_date] => 2024-10-25
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 27562
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -12
[patent_words_short_claim] => 73
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18927451
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/927451 | TREATMENT OF NEUROLOGICAL DISORDERS | Oct 24, 2024 | Pending |
Array
(
[id] => 19743867
[patent_doc_number] => 20250032432
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2025-01-30
[patent_title] => BUPROPION AS A MODULATOR OF DRUG ACTIVITY
[patent_app_type] => utility
[patent_app_number] => 18/916325
[patent_app_country] => US
[patent_app_date] => 2024-10-15
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 63773
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 73
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18916325
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/916325 | BUPROPION AS A MODULATOR OF DRUG ACTIVITY | Oct 14, 2024 | Pending |
Array
(
[id] => 19745537
[patent_doc_number] => 20250034102
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2025-01-30
[patent_title] => ADVANTAGEOUS BENZOFURAN COMPOSITIONS FOR MENTAL DISORDERS OR ENHANCEMENT
[patent_app_type] => utility
[patent_app_number] => 18/895095
[patent_app_country] => US
[patent_app_date] => 2024-09-24
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 94339
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -26
[patent_words_short_claim] => 48
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18895095
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/895095 | Advantageous benzofuran compositions for mental disorders or enhancement | Sep 23, 2024 | Issued |
Array
(
[id] => 19745537
[patent_doc_number] => 20250034102
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2025-01-30
[patent_title] => ADVANTAGEOUS BENZOFURAN COMPOSITIONS FOR MENTAL DISORDERS OR ENHANCEMENT
[patent_app_type] => utility
[patent_app_number] => 18/895095
[patent_app_country] => US
[patent_app_date] => 2024-09-24
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 94339
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -26
[patent_words_short_claim] => 48
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18895095
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/895095 | Advantageous benzofuran compositions for mental disorders or enhancement | Sep 23, 2024 | Issued |
Array
(
[id] => 19599442
[patent_doc_number] => 20240390322
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-11-28
[patent_title] => PSYCHOACTIVE MEDICINES AND THEIR USE FOR TREATING PSYCHIATRIC AND NEUROLOGICAL CONDITIONS AND DISORDERS
[patent_app_type] => utility
[patent_app_number] => 18/790708
[patent_app_country] => US
[patent_app_date] => 2024-07-31
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 62009
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -23
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18790708
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/790708 | Psychoactive medicines and their use for treating psychiatric and neurological conditions and disorders | Jul 30, 2024 | Issued |
Array
(
[id] => 19691166
[patent_doc_number] => 20250009711
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2025-01-09
[patent_title] => PSYCHOACTIVE MEDICINES AND THEIR USE FOR TREATING PSYCHIATRIC AND NEUROLOGICAL CONDITIONS AND DISORDERS
[patent_app_type] => utility
[patent_app_number] => 18/784243
[patent_app_country] => US
[patent_app_date] => 2024-07-25
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 62070
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -4
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18784243
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/784243 | Psychoactive medicines and their use for treating psychiatric and neurological conditions and disorders | Jul 24, 2024 | Issued |
Array
(
[id] => 16946549
[patent_doc_number] => 20210205240
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-07-08
[patent_title] => BUPROPION AS A MODULATOR OF DRUG ACTIVITY
[patent_app_type] => utility
[patent_app_number] => 17/193306
[patent_app_country] => US
[patent_app_date] => 2021-03-05
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 63769
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -50
[patent_words_short_claim] => 24
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17193306
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/193306 | Bupropion as a modulator of drug activity | Jun 9, 2024 | Issued |
Array
(
[id] => 19554739
[patent_doc_number] => 20240366531
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-11-07
[patent_title] => COMPOSITIONS AND METHODS FOR TREATMENT OF DISEASES AND DISORDERS
[patent_app_type] => utility
[patent_app_number] => 18/652721
[patent_app_country] => US
[patent_app_date] => 2024-05-01
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 24389
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -28
[patent_words_short_claim] => 173
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18652721
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/652721 | Compositions and methods for treatment of diseases and disorders | Apr 30, 2024 | Issued |
Array
(
[id] => 19883015
[patent_doc_number] => 12268697
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2025-04-08
[patent_title] => Oxysterols and methods of use thereof
[patent_app_type] => utility
[patent_app_number] => 18/603816
[patent_app_country] => US
[patent_app_date] => 2024-03-13
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 24580
[patent_no_of_claims] => 4
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 6
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18603816
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/603816 | Oxysterols and methods of use thereof | Mar 12, 2024 | Issued |
Array
(
[id] => 19666155
[patent_doc_number] => 12178875
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2024-12-31
[patent_title] => Lymphatic system-directing lipid prodrugs
[patent_app_type] => utility
[patent_app_number] => 18/425761
[patent_app_country] => US
[patent_app_date] => 2024-01-29
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 21
[patent_figures_cnt] => 22
[patent_no_of_words] => 92403
[patent_no_of_claims] => 11
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 39
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18425761
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/425761 | Lymphatic system-directing lipid prodrugs | Jan 28, 2024 | Issued |